REG - Silence Therapeutics - Silence Therapeutics Files Registration with SEC

Silence TherapeuticsAnnouncement

21/08/2020 07:00

RNS Number : 7650W
  
Silence Therapeutics PLC
  
21 August 2020
  
 

 
Silence Therapeutics Publicly Files Registration Statement with the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing Ordinary Shares
 
21 August 2020
 
LONDON, Silence Therapeutics plc (LON:SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (the "SEC") in connection with a proposed listing of American Depositary Shares ("ADSs") representing the Company's ordinary shares of nominal value £0.05 each ("Ordinary Shares") on the Nasdaq Capital Market ("Nasdaq"). 
 
The registration statement was filed to facilitate the creation of a trading market in the United States for ADSs representing the Company's Ordinary Shares. The Company is not proposing to register any new primary issuance of securities. The registration statement is subject to ongoing review by the SEC, and the proposed listing of ADSs representing the Company's Ordinary Shares is subject to approval by Nasdaq. The Company's Ordinary Shares will continue to be admitted to trading on AIM, a market operated by the London Stock Exchange.
 
Enquiries:
 



Silence Therapeutics plc
Iain Ross, Executive Chairman
Dr Rob Quinn, Chief Financial Officer
 
 


Tel:  +44 (0)20 3457 6900




  Investec Bank plc (Nominated Adviser and Broker)
Daniel Adams/Gary Clarence
 


  Tel:  +44 (0) 20 7597 5970




European IR
Consilium Strategic Communications
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com 
 


Tel: +44 (0) 20 3709 5700




US IR
Westwicke Partners
Peter Vozzo
peter.vozzo@westwicke.com
 


 Tel: +1 (443) 213-0505



 
 
 
 
 
 
 
 
 
Notes to Editors
 
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. 
 
This announcement is being made pursuant to and in accordance with Rule 134 under the Securities Act of 1933, as amended. This announcement does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
 
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements including with respect to the creation of a trading market for ADSs representing the Company's Ordinary Shares in the United States. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions.  Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including if the Company's registration statement is not declared effective by the SEC or if Nasdaq fails to approve the Company's ADS listing application. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
 
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
MSCPPUCPRUPUPPU